UBS Group
TELO icon

UBS Group’s Telomir Pharmaceuticals TELO Stock Holding History

UBS Group’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12K Sell
9,213
-4,835
-34% -$6.17K ﹤0.01% 8273
2025
Q4 		$18.7K Sell
14,048
-49,488
-78% -$71.4K ﹤0.01% 7831
2025
Q3 		$88.3K Buy
63,536
+14,805
+30% +$22.3K ﹤0.01% 7209
2025
Q2 		$60.9K Buy
48,731
+33,315
+216% +$77K ﹤0.01% 7613
2025
Q1 		$49.8K Sell
15,416
-9,510
-38% -$41.6K ﹤0.01% 7598
2024
Q4 		$103K Buy
24,926
+21,122
+555% +$99.5K ﹤0.01% 6857
2024
Q3 		$24.4K Sell
3,804
-2,127
-36% -$10.4K ﹤0.01% 7253
2024
Q2 		$28.5K Buy
+5,931
New +$37K ﹤0.01% 7093

Other funds holding TELO

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
WIA
World Investment Advisors Santa Barbara, California $6.2B AUM 19.68% 1-Year Est. Return

UBS Group's TELO Position: Q1 2026 in Review

UBS Group reduced its Telomir Pharmaceuticals (TELO) stake by 34% in Q1 2026, selling an estimated $6.17K and leaving 9,213 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #8273.

UBS Group first reported a position in TELO in Q2 2024 and has held it in 8 quarters since. The position peaked at $103K in Q4 2024. 27 funds tracked by Wall St. Rank hold TELO as of Q1 2026.

  • UBS Group held 9,213 shares of Telomir Pharmaceuticals worth $12K as of Q1 2026.
  • UBS Group sold 4,835 Telomir Pharmaceuticals shares in Q1 2026, an estimated $6.17K.
  • Telomir Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8273 holding.
  • UBS Group first reported a position in Telomir Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • UBS Group's Telomir Pharmaceuticals position peaked at $103K in Q4 2024.
  • 27 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.